Mutants of streptococcal toxin a and methods of use
AssigneeRegents of the University of Minnesota
InventorsPatrick M. Schlievert, Manuela Roggiani, Jennifer Stoehr, Douglas Ohlendorf
Life of this patent
Estimating the term…
Abstract
This invention is directed to mutant SPE-A toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-A toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-A toxin. The mutant SPE-A toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-A toxin.
Claims57
A vaccine comprising a mutant SPE-A toxin comprising substitution of asparagine-20 to aspartic acid;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A method for treating an animal for the effects of at least one biological activity of a wild type SPE-A comprising:
- administering a SPE-A toxin comprising substitution of asparagine-20 to aspartic acid;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering uscd in SEQ ID NO:
- 14.
A pharmaceutical composition comprising a mutant SPE-A toxin comprising substitution of asparagine-20 to aspartic acid;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A vaccine comprising a mutant SPE-A toxin comprising substitution of aspartic acid-45 to asparagine;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A method for treating an animal for the effects of at least one biological activity of a wild type SPE-A comprising:
- administering a SPE-A toxin comprising substitution of aspartic acid-45 to asparagine;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A pharmaceutical composition comprising a mutant SPE-A toxin comprising substitution of aspartic acid-45 to asparagine;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A vaccine comprising a mutant SPE-A toxin comprising substitution of cysteine-98 to serine and asparagine-20 to aspartic acid;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A method for treating an animal for the effects of at least one biological activity of a wild type SPE-A comprising:
- administering a SPB-A toxin comprising substitution of cysteine-98 to serine;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A pharmaceutical composition comprising a mutant SPE-A toxin comprising substitution of cysteine-98 to serine and asparagine-20 to aspartic acids;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A vaccine comprising a mutant SPE-A toxin comprising substitution of asparagine-20 to aspartic acid and substitution of cysteine-98 to serine;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A method for treating an animal for the effects of at least one biological activity of a wild type SPE-A comprising:
- administering a SPE-A toxin comprising substitution of asparagine-20 to aspartic acid and substitution of cysteine-98 to serine;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A pharmaceutical composition comprising a mutant SPE-A toxin comprising substitution of asparagine-20 to aspartic acid and substitution of cysteine-98 to serine;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A vaccine comprising a mutant SPE-A toxin comprising substitution of asparagine-20 to aspartic acid, substitution of aspartic acid-45 to asparagine, and substitution of cysteine-98 to serine;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A method for treating an animal for the effects of at least one biological activity of a wild type SPE-A comprising:
- administering a SPE-A toxin comprising substitution of asparagine-20 to aspartic acid, substitution of aspartic acid-45 to asparagine, and substitution of cystcine-98 to serine;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A pharmaceutical composition comprising a mutant SPE-A toxin comprising substitution of asparagine-20 to aspartic acid, substitution of aspartic acid-45 to asparagine, and substitution of cysteine-98 to serine;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A method for treating an animal for the effects of at least one biological activity of a wild type SPE-A comprising:
- administering a SPE-A toxin comprising substitution of lysine-157 to glutamic acid;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A pharmaceutical composition comprising a mutant SPE-A toxin comprising substitution of lysine-157 to glutamic acid;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A method for treating an animal for the effects of at least one biological activity of a wild type SPE-A comprising:
- administering a SPE-A toxin comprising substitution of lysine-16 to asparagine, substitution of cysteine-87 to serine, or substitution of cysteine-90 to serine;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
A pharmaceutical composition comprising a mutant SPE-A toxin comprising substitution of lysine-16 to asparagine;
- wherein the numbering of amino acids of SPE-A toxin is according to the numbering used in SEQ ID NO:
- 14.
Dependencies are inferred from the claim text.